EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

The purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment. Life quality, adverse effects and tumor response will be evaluated and analyses of obtained blood and tumor samples will be performed to identify molecular profiles and biomarkers that can be used for treatment decisions.

Trial Details

NCT ID
NCT06486142
Phase
PHASE3
Sponsor
Region Skane
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Afatinib/Dacomitinib
  • Osimertinib
Locations (sample)
  • Lund, Sweden|55.70584,13.19321

Key Eligibility Criteria

  • The subject has given written consent to participate in the study.
  • Histological or cytological diagnosis of NSCLC.
  • Clinical stage III/IV disease (with or without CNS metastasis) or a recurrence not amenable for curative treatment intention.
  • Measurable disease according to RECIST 1.1 criteria or equivalent/modified criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →